Suspended

An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Vagal Nerve Simulation (VNS) Therapy

+ Best Medical Practive

DeviceDrug
Who is being recruted

Brain Diseases+2

+ Central Nervous System Diseases

+ Epilepsy

Over 16 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
Study Start: February 2006
See protocol details

Summary

Principal SponsorCyberonics, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2006

Actual date on which the first participant was enrolled.

This is a post-market medical device study. This study will compare best medical practice with or without adjunctive VNS Therapy in patients who are 16 years and older with pharmaco-resistant partial epilepsy. The Sponsor, Cyberonics, provides funding for this study. Patients are followed for 26 months, 24 of those months are following the initiation of treatment. No study sites will be permitted to enroll study subjects until Institutional Review Board (IRB)/Ethics Committee (EC) approval has been received.

Official TitleAn Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy
Principal SponsorCyberonics, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

122 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 16 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Brain DiseasesCentral Nervous System DiseasesEpilepsyEpilepsies, PartialNervous System Diseases

Criteria

Inclusion Criteria: * Patient has confirmed partial onset seizures. * Seizure activity is not adequately controlled by patient's current AED regimen. * Patient is between 16 and 75 years of age. * Patient is able to give accurate seizure counts and health outcomes information. Patient is able to complete study instruments with minimal assistance. * Patient has previously failed at least 3 AEDs in single or combination use. * During baseline evaluation period, patient should take at least 1 AED. * Patient should have confirmed epilepsy for a minimum of 2 years. * Patient's AED regimen is stable for at least 1 month prior to enrolment. * Patient has at least 1 objective partial onset seizure per month during the 2 months prior to enrolment. * Patient or legal guardian understands study procedures and has voluntarily signed an informed consent in accordance with institutional and local regulatory policies. Exclusion Criteria: * Patient has pseudoseizures or a history of pseudoseizures. * Patient has idiopathic generalised epilepsy or unclassified epilepsy. * Patient has ever received direct brain stimulation (cerebella or thalamic) for treatment of epilepsy. * Patient has had a unilateral or bilateral cervical vagotomy. * Patient has a history of non-compliance with the completion of a seizure diary. * Patient has taken an investigational drug within a period of 3 months prior to inclusion. * Patient is currently using another investigational medical device. * Patient has a significant cardiac or pulmonary condition currently under treatment. * Patient has previously undergone brain surgery. * Patient has a demand cardiac pacemaker, implantable defibrillator, or other implantable stimulator. * Patient currently lives more than 2 hours from the study site or plans to relocate to a location more than 2 hours from the study site within one year of enrolment in the Study.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
VNS Therapy + Best Medical Practice

Group II

Active Comparator
Best Medical Practice

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 48 locations

Suspended

ULB-Hôpital Erasme, Centre de référence pour le traitement de l'épilepsie réfractaire - Neurologie

Brussels, BelgiumOpen ULB-Hôpital Erasme, Centre de référence pour le traitement de l'épilepsie réfractaire - Neurologie in Google Maps
Suspended

UZ Gent, Department of Neurology, 1K12/A

Ghent, Belgium
Suspended

Foothills Hospital, Neurology Department

Calgary, Canada
Suspended

QEII Health Sciences Centre

Halifax, Canada
Suspended48 Study Centers